ACW Alzheimers pivotal trial completes last patient visit
Filed with ASX · · 3 pages · English
Summary by 6ix AI
Actinogen Medical Limited announces the completion of the final patient visit for its XanaMIA pivotal Alzheimer’s disease trial, confirming that topline results are expected in November. Dr. Dana Hilt, the Chief Medical Officer, emphasized the potential of Xanamem as a transformative treatment option for Alzheimer’s patients. The trial has now closed to participant recruitment and will report final results soon.
Written by 6ix AI from the company’s filing. How 6ix writes summaries
Actinogen Medical Limited on 6ix
Earlier from Actinogen Medical
- ACW unlisted options fully underwritten
- ACW FY2026 results and outlook
- ACW Appendix 4E and 2026 annual report
- June 2026 Quarterly activity report & Appendix 4C
- Xanamem depression trial published in British J Psychiatry
Later from Actinogen Medical
- Underwriting of unlisted options completed
- Actinogen XanaMIA pivotal Alzheimer’s disease trial completes final patient visit, with topline results on track for November
- ACW September 2026 quarterly activity report & Appendix 4C
- ACW pivotal Alzheimers trial database lock - results mid-Nov
Follow Actinogen Medical into a list and get an email when it puts out news.
Follow Actinogen Medical